Blood, dose recommendation reports and phone calls: experiences of a therapeutic drug monitoring advisory service for vancomycin

Date

2023

Authors

Carland, J.E.
Stacy, A.E.
Schaffer, A.L.
Day, R.O.
Brett, J.
Reuter, S.E.
Stocker, S.L.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

British Journal of Clinical Pharmacology, 2023; 89(6):1896-1902

Statement of Responsibility

Conference Name

Abstract

Dose-prediction software is recommended to enable area under the curve over 24 h (AUC(24))-guided dosing of the antibiotic vancomycin. However, uncertainty remains about how best to implement software in the clinic. We describe the activity, over 18 months, of a consultative therapeutic drug monitoring Advisory Service (the Service) for vancomycin that used dose-prediction software alongside clinical expertise, identifying factors that influence attainment of therapeutic targets. Of the 408 vancomycin dose reports provided for 182 courses of therapy, most (57%) recommended a dose change. The majority (82.8%, 193/233) of recommended dose adjustments were accepted by treating teams. A dose report was not published for 125 courses of therapy, with reasons including patient in intensive care unit or service error. An estimated 26.6 h of staff time was allocated to Service activities each month. Publication of a dose report facilitated attainment of therapeutic targets (P = .002). Software integration could improve Service outcomes, avoiding errors and reducing staff workload.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

Copyright 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution-Non Commercial-No Derivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/)

License

Grant ID

Call number

Persistent link to this record